Business
Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels
Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembroliz
About this update from Caris Life Sciences, Inc.
[{"type":"text","content":"Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination","length":152,"tagName":"p","attribs":{}},{"type":"text","content":"IRVING, Texas, May 11, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Cancer Immunology, Immunotherapy demonstrating that measuring tumor mutational burden (TMB) using ultra-deep Whole Exome Sequencing (WES) provides superior prediction of pembrolizumab immunotherapy benefit compared to estimates of TMB from targeted gene panels. TMB is a pan-tumor biomarker used to determine patients' eligibility for pembrolizumab. These findings highlight the importance of testing all cancer patients with ultra-deep WES, the only truly comprehensive genomic profile for therapy selection.","length":713,"tagName":"p"},{"type":"image","alt":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","displaySize":"","headline":null,"caption":"Caris Life Sciences Logo (PRNewsfoto/Caris Life Sciences)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":359,"url":"https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DYkfDi5YhqiUCC4hCHfZpQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTYzMw--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/xS87Ss8EcVJzBN8xSSK9jA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTU3NA--/https://media.zenfs.com/en/prnewswire.com/7e09703fc3526e7b3703f1e6a94d5ea8","width":400,"height":359}},"href":"https://mma.prnewswire.com/media/830740/Caris_Life_Sciences_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The study used Caris' large-scale, real-world clinico-genomic database, containing 26,756 patients treated with pembrolizumab who were evaluable for this study. WES provides a true measurement of TMB by interrogating every protein-coding gene mutation that may create a neoantigen, in comparison to targeted panels that only estimate TMB with incomplete gene coverage.","length":372,"tagName":"p"},{"type":"text","content":"Key findings include:","length":21,...